{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000078","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.379096+00:00","generated_at":"2026-05-17T17:33:54.375248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intensity Therapeutics raises $11.3M, extends cash runway to H2 2026; Q2 net loss narrows to $2.5M","bullets":["Net proceeds of ~$10.1M from two public offerings and ATM; cash runway now into H2 2026.","Q2 2025 net loss $2.5M vs $5.0M in Q2 2024; R&D expense fell to $1.5M from $3.6M.","INVINCIBLE-3 (soft tissue sarcoma) enrollment paused in March after 23 patients; existing patients continue dosing.","INVINCIBLE-4 (triple-negative breast cancer) recruiting in France and Switzerland; EMA authorized initiation.","INT230-6 showed 100% complete response in preclinical MPNST models; company believes Nasdaq compliance restored."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000078","json":"https://secwatch.observer/filing/0001567264-25-000078.json","markdown":"https://secwatch.observer/filing/0001567264-25-000078.md","text":"https://secwatch.observer/filing/0001567264-25-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000078/0001567264-25-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000078/intensity-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:33:54.375248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}